Teresa Caballero‐Velázquez

Author

Instituto de Biomedicina de Sevilla ORCID

Also Known As

Flor Araceli Nava Ayala, Francisco J. Márquez Malaver, T Caballero Velázquez, T Caballero-Velazquez, T Caballero‐Velázquez, T VELAZQUEZ, T Velázquez, T. Caballero-Velazquez, T. Caballero-Velázquez, T. Caballero‐Velázquez

178

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Instituto de Biomedicina de Sevilla Universidad de Sevilla Hospital Universitario Virgen del Rocío Instituto de Investigación Biomédica de Salamanca Centro de Investigación del Cáncer

About

Teresa Caballero‐Velázquez is an author at Instituto de Biomedicina de Sevilla specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	402
2	Cell Biology	7	7	135
3	Health Sciences	4	4	112
4	Public Health	1	1	37
5	Cellular Therapies	1	1	17

Teresa Caballero‐Velázquez

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting Luís I. Sánchez-Abarca, Silvia Gutierrez-Cosío, Carlos Santamaría, Blood	2009	224
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease Fermín Sánchez‐Guijo, Teresa Caballero‐Velázquez, Olga López‐Villar, Biology of Blood and Marrow Transplantation	2014	117
3-Year Clinical Follow-Up of the RIBS IV Clinical Trial Fernándo Alfonso, Marı́a José Pérez-Vizcayno, Javier Cuesta, JACC: Cardiovascular Interventions Rib Fracture ManagementClinical EvidenceClinical Trials3-Year Clinical Follow-upThoracic Surgery	2018	109
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma Bruno Paiva, Mauricio Chandía, María‐Belén Vídriales, Blood	2014	93
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population Belén Blanco, Josè Antonio Pérez-Simón, Luís I. Sánchez-Abarca, Haematologica	2009	57
Sensitivity of hematopoietic stem cells to mitochondrial dysfunction by SdhD gene deletion José A. Bejarano-García, África Millán‐Uclés, Iván V. Rosado, Cell Death and Disease	2016	48
Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial Teresa Caballero‐Velázquez, Isabel Montero, Fermín Sánchez‐Guijo, Clinical Cancer Research	2016	44
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia Bruno Paiva, María‐Belén Vídriales, Amparo Sempere, Leukemia Hematological MalignancyMedicineAcute Myeloid LeukemiaPethema Real-world StudyHematology	2021	40
Phase <scp>II</scp> clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (<scp>RIC</scp>) and post‐allogeneic transplantation for high‐risk myeloma patients Teresa Caballero‐Velázquez, Lucía López‐Corral, Cristina Encinas, British Journal of Haematology	2013	39
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies Clara García-Calderón, Belén Sierro-Martínez, Estefanía García‐Guerrero, Frontiers in Immunology	2023	38

Page 1